Insulet (PODD) | Stock Overview & Key Data
Insulet Performance Comparison
Stock Range
Today's Range
Low: $328.08
High: $333.22
on August 22, 2025
52 Week Range
Low: $180.31
High: $334.18
on August 26, 2024
on August 21, 2025
All-Time High: $335.91 on May 1, 2023
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$23.1B
EPS
3.27
P/E Ratio (TTM)
100.15
Forward P/E
84.62
P/B Ratio
15.76
PEG Ratio
-1.14
Div. Yield
N/A
ROE
19.18%
Beta
1.348
Debt to Equity
95.68
Financial Highlights
Profitability
Gross Margin
69.67%
Operating Margin
18.66%
Profit Margin
10.01%
Returns and Earnings
Return on Assets (TTM)
7.75%
Return on Equity (TTM)
19.18%
EBITDA
$531.2M
Net Income (TTM)
$236.1M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$33.61
Quarterly Revenue Growth (YoY)
32.90%
Quarterly Earnings Growth (YoY)
-88.10%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Insulet PODD | 23.05B Large-cap | 2.96% | 15.83% | 3.04% | 16.68% | 28.78% | 78.76% | 23.81% | 54.32% |
| Abbott Laboratories ABT | 229.74B Mega-cap | 0.64% | 5.46% | 0.83% | -1.75% | 16.88% | 17.64% | 30.10% | 19.66% |
| Boston Scientific BSX | 156.30B Large-cap | 2.91% | 2.92% | 1.60% | 1.71% | 18.78% | 34.05% | 161.92% | 158.66% |
| Stryker SYK | 145.89B Large-cap | 3.22% | -0.24% | 4.21% | 1.62% | 9.89% | 11.59% | 90.44% | 98.89% |
| Medtronic plc MDT | 118.79B Large-cap | -0.33% | 1.16% | 14.58% | 2.82% | 15.57% | 4.93% | 3.67% | -14.05% |
| Edwards Lifesciences EW | 47.97B Large-cap | 4.56% | 7.25% | 9.41% | 12.47% | 12.73% | 15.45% | -10.31% | -2.96% |
Ownership & Short Interest
Insider Ownership
0.28%
Institutional Ownership
101.94%
Shares Short
2M
Short Ratio
3.03
Short % of Shares Outstanding
3.79%
Average 10-Day Volume
853K
Average 90-Day Volume
635K
Insulet Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Insulet would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PODD's 52-week high and low?
- In the last 52 weeks, Insulet reached a high of $334.18 (on August 21, 2025) and a low of $180.31 (on August 26, 2024).
- What is the market cap and P/E ratio for PODD?
- Curious about Insulet's size and valuation? Its market capitalization stands at 23.05B. When it comes to valuation, the P/E ratio (trailing twelve months) is 100.15, and the forward P/E (looking ahead) is 84.62.
- Does PODD pay dividends? If so, what's the yield?
- As for dividends, Insulet isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Insulet's main competitors or similar companies to consider before investing?
When looking at Insulet, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT229.74B Healthcare Medical Devices 17.64% 30.10% Boston Scientific
BSX156.30B Healthcare Medical Devices 34.05% 161.92% Stryker
SYK145.89B Healthcare Medical Devices 11.59% 90.44% Medtronic plc
MDT118.79B Healthcare Medical Devices 4.93% 3.67% Edwards Lifesciences
EW47.97B Healthcare Medical Devices 15.45% -10.31% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Insulet Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Insulet's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 19.18%, the Debt to Equity ratio from the most recent quarter is 95.68, and its Gross Profit Margin stands at 69.67%.
- What is the recent revenue and earnings growth for PODD?
- Looking at Insulet's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 32.90%, and quarterly earnings saw a YoY growth of -88.10%.
- How much of PODD stock is held by insiders and institutions?
- Wondering who owns Insulet stock? Company insiders (like executives and directors) hold about 0.28% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 101.94%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.